| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 13 Nov 2026 |
Form 4: Gaynor Richard, Director
Bought 1,228 shares ($33.4K) |
| 09 Nov 2026 | D |
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
–Zoci 1.6 mg/kg plus atezolizumab showed compelling 1L SCLC data at ESMO: 81.8% confirmed ORR, an estimated 81.9% six-month PFS rate and 9.1% Grade ≥3 zoci-related AEs; advancing toward a global Phase 3 study in 1L SCLC |
| 23 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more
SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of October 22, 2026, by and among Zai Lab Limited, an exempted company incorporated with limited liability under the laws of the Cayman Islan... |
| 05 Oct 2026 |
Form 4: Chen Yajing, Chief Financial Officer
Received 920 shares by exercise or conversion · Gave up 315 shares to cover exercise price or tax ($8.03K) |
| 21 Aug 2026 |
Form 4: Chen Yajing, Chief Financial Officer
Sold 260 shares ($7.02K) |
| 20 Aug 2026 | 144 |
| 19 Aug 2026 | 144 |
| 18 Aug 2026 |
Form 4: Chen Yajing, Chief Financial Officer
Received 1,250 shares by exercise or conversion · Gave up 427 shares to cover exercise price or tax ($11.1K) |
| 13 Aug 2026 |
Form 4: Lis William, Director
Sold 8,506 shares ($213K) |
| 13 Aug 2026 |
Form 4: Chen Yajing, Chief Financial Officer
Sold 619 shares ($15.5K) |
| 12 Aug 2026 | 144 |
| 11 Aug 2026 | 144 |
| 06 Aug 2026 | 10-Q |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
–The Company advanced multiple global oncology and immunology programs toward key clinical and regulatory milestones, with significant pipeline catalysts expected in the second half of 2026 |
| 06 Jul 2026 |
Form 4: Gaynor Richard, Director
Bought 1,736 shares ($33.1K) |
| 06 Jul 2026 |
Form 4: Du Ying, Director
Received 18,000 shares by exercise or conversion · Gave up 7,083 shares to cover exercise price or tax ($136K) · Received 11,048 shares by exercise or conversion · 2 more |
| 01 Jul 2026 |
Form 4: Du Ying, Director
Received 17,970 shares by exercise or conversion · Sold 7,026 shares ($130K) |
Loading...